Tvardi Therapeutics Inc. Common Stock (TVRD)

About TVRD

Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting signal transducer and activator of transcription 3 (STAT3) to treat inflammatory and proliferative diseases with significant unmet need in the United States. The company's lead product candidates include TTI-101, which is in Phase 1b/2 clinical development stage for…

Sector

Health Care

Industry

Biotechnology: Pharmaceutical Preparations

Employees

12

Website

tvarditherapeutics.com

Fundamentals

1-day range

$1.78$1.92

Market cap

$23.02M

P/E (trailing)

—

P/E (forward)

-0.80

EPS (trailing)

$-1.60

Dividend yield

—

Beta

0.35

Avg. volume

2.37M

Forecasts

8 analyst ratings

Tvardi Therapeutics Inc. Common Stock Competitors

Chosen by industry and closest market cap.

• TVRD

  Tvardi Therapeutics Inc. Common Stock

  $1.8

  ▲ 0.00%
  Market cap $23.02MP/E —
  $1.5$43.65
• BRNS

  Barinthus Biotherapeutics plc American Depositary Shares

  $0.7464

  ▲ 2.11%
  Market cap $23.08MP/E —
  $0.512$1.83
• IGC

  IGC Pharma Inc. Common Stock

  $0.3086

  ▼ 6.48%
  Market cap $23.94MP/E —
  $0.24$0.5
• CALC

  CalciMedica Inc. Common Stock

  $0.4644

  ▼ 1.19%
  Market cap $21.88MP/E —
  $0.4606$7.2
• TXMD

  TherapeuticsMD Inc. Common Stock

  $2.22

  ▼ 0.89%
  Market cap $24.19MP/E —
• LGVN

  Longeveron Inc. Class A Common Stock

  $6.72

  ▼ 1.47%
  Market cap $24.44MP/E —
  $4.75$12.3
• NEUP

  Neuphoria Therapeutics Inc. Common Stock

  $3.82

  ▲ 1.33%
  Market cap $21.08MP/E —
  $3.19$21.4

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• Tvardi Therapeutics, Inc. (TVRD) Discusses TTI-109 Development Program and Data in Ulcerative Colitis - Slideshow
  SeekingAlpha · 8/19/2026
• Tvardi Therapeutics, Inc. (TVRD) Discusses TTI-109 Development Program and Data in Ulcerative Colitis Transcript
  SeekingAlpha · 8/19/2026
• 12 Health Care Stocks Moving In Tuesday's After-Market Session
  Benzinga · 8/18/2026
• Tvardi Therapeutics Q2 EPS $(0.69) Beats $(0.70) Estimate
  benzinga · 8/14/2026
• Tvardi Therapeutics Announces Second Quarter 2026 Results and Provides Business Update
  Yahoo · 8/14/2026
• Tvardi Therapeutics Q2 EPS $(0.69) Beats $(0.70) Estimate
  Benzinga · 8/14/2026
• Tvardi Therapeutics to Host KOL Webinar on the Clinical Potential of TTI-109 in Ulcerative Colitis (UC) and the Evolving Treatment Landscape, on August 19, 2026
  Yahoo · 8/12/2026
• Tvardi Therapeutics To Host KOL Webinar On August 19 To Discuss Current Treatment Landscape In Ulcerative Colitis And Persistent Unmet Needs; Event To Feature New Data From Tvardi And Review Of Phase 1 Healthy Volunteer Results Supporting Potential Of TTI-109 In UC
  Benzinga · 8/12/2026

• Shiff Susan Ph.D. · June 9, 2026 · Grant

  6.0K
• HALL WALLACE L JR · June 9, 2026 · Grant

  6.0K
• Smith Cynthia · June 9, 2026 · Grant

  6.0K
• Shah Sujal · June 9, 2026 · Grant

  6.0K
• Michael S. Wyzga · June 9, 2026 · Grant

  6.0K

Institutional Ownership

March 31, 2026

Total shares held

2.62M

Total value held

$8.32M

Institutional holders

63